We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
  • SKIP TO CONTENT
  • SKIP NAVIGATION
  • Drug News
    • Trending
    • Commercial Operations
    • GMPs
    • FDA Enforcement Actions
    • Inspections and Audits
    • Postmarket Safety
    • Quality
    • Regulatory Affairs
    • Research and Development
    • Submissions and Approvals
    • FDAnews Drug Weekly
    • FDAnews
  • Device News
    • Trending
    • Commercial Operations
    • FDA Enforcement Actions
    • Inspections and Audits
    • Postmarket Safety
    • Quality
    • Regulatory Affairs
    • Research and Development
    • Submissions and Approvals
    • FDAnews Device Weekly
    • FDAnews
  • Books
    • FDAnews Books Library
    • Drug Books
    • Device Books
  • Training/Events
    • Webinar Training Pass
    • Events
    • Webinar Recordings
  • Resources
    • Form 483s Database
    • FDA Approved Drugs
    • White Papers
  • CenterWatch
  • About Us
    • The Company
    • FDAnews Editorial Board
    • Contact Us
  • Advertising
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Penn. House Approves ‘Right-To-Try’ Bill

Penn. House Approves ‘Right-To-Try’ Bill

April 26, 2017

The Pennsylvania House of Representatives approved a bill allowing terminally ill patients to use drugs not yet approved by the FDA.

House Bill 45, which passed the chamber unanimously, would allow drugmakers to sell experimental drugs to terminal patients once they successfully complete a Phase I clinical trial. It also exempts doctors from any liability for recommending experimental drugs to eligible patients.

Rep. Robert Godshall, the bill’s sponsor, introduced similar legislation in the House’s last session, but despite unanimous passage by the House, it was never brought to the floor of the state Senate. If the bill passes, Pennsylvania will become the 32nd state with a “right-to-try” law on the books.

View today's stories

Drugs Commercial Operations

    Upcoming Events

    • 11Oct

      GMP Quality Management vSummit 2023: Where Quality Meets Risk

    • 16Oct

      MAGI@home Clinical Research Conference 2023

    • 26Oct

      FDA in 2024: What to Expect in an Election Year

    • 02Nov

      How UDI and UDI Data Can — and Must — Be Used for More Than Just Device Identification

    • 08Nov

      18th Annual FDA Inspections vSummit

    Featured Products

    • FDA, FTC and DOJ Enforcement of Medical Device Regulations

      FDA, FTC and DOJ Enforcement of Medical Device Regulations

    • Using Real-World Evidence in Drug and Device Submissions

      Using Real-World Evidence in Drug and Device Submissions

    Featured Stories

    • Adcomm Votes Down ALS Stem Cell Therapy, Debates Clinical Data vs. Personal Data

    • Reports Allege Philips Withheld Evidence of Ventilator Malfunctions for 11 Years

    • Summary Judgment Sought by Boehringer Ingelheim in its IRA Lawsuit

    • FDA Proposes New Rule on Who has Oversight on Lab Tests

    The Revised ICH E8: A Guide to New Clinical Trial Requirements

    Learn More
    • Drug Products
      • Quality
      • Regulatory Affairs
      • GMPs
      • Inspections and Audits
      • Postmarket Safety
      • Submissions and Approvals
      • Research and Development
      • Commercial Operations
    • Device Products
      • Quality
      • Regulatory Affairs
      • QSR
      • Inspections and Audits
      • Postmarket Safety
      • Submissions and Approvals
      • Research and Development
      • Commercial Operations
    • Clinical Products
      • Trial Design
      • Data Integrity
      • GCP
      • Inspections and Audits
      • Transparency
    • Privacy Policy
    • Do Not Sell or Share My Data
    Footer Logo

    300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

    Phone 703.538.7600 – Toll free 888.838.5578

    Copyright © 2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing